StockData
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.14−0.21 (-8.94%)

Close on Nov 13, 2026Market cap $171.57MP/E –Yield –

BridgeBio Oncology Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

BridgeBio Oncology Therapeutics's price to book ratio was 0.6× on Nov 11, 2026, against 2.2× a year earlier.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.6×−1.6
2025Dec 31, 20252.2×–

More BridgeBio Oncology Therapeutics figures

See a number that looks wrong?